SCHEMBL7864938

SCHEMBL7864938

O=C(OCc1ccccc1)c1ccncc1

nearest known ligand 0.76

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.76
TDP1 Q9NUW8 3/20 0.76
SLC6A2 P23975 1/20 0.76
SLC6A3 Q01959 1/20 0.76
KDM4E B2RXH2 2/20 0.71
LMNA P02545 2/20 0.69
L3MBTL1 Q9Y468 2/20 0.63
TSHR P16473 1/20 0.61
ALDH1A1 P00352 3/20 0.59
POLB P06746 2/20 0.59
HPGD P15428 2/20 0.59
MAPT P10636 1/20 0.59
MEN1 O00255 1/20 0.55
GAA P10253 1/20 0.54
RAB9A P51151 1/20 0.54
NPSR1 Q6W5P4 1/20 0.52
JMJD6 Q6NYC1 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14062862 0.93 KMT2A (0.76) KMT2ATDP1SLC6A2SLC6A3KDM4E
Benzyl Benzoate SCHEMBL8010992 0.87 KMT2A (1.00) KMT2ATDP1SLC6A2SLC6A3KDM4E
Benzyl Benzoate SCHEMBL901058 0.87 KMT2A (1.00) KMT2ATDP1SLC6A2SLC6A3KDM4E
Benzyl Benzoate SCHEMBL3038 0.87 KMT2A (1.00) KMT2ATDP1SLC6A2SLC6A3KDM4E
SCHEMBL312287 0.87 KMT2A (0.92) KMT2ATDP1SLC6A2SLC6A3LMNA
Benzyl Benzoate SCHEMBL29101943 0.85 KMT2A (0.96) KMT2ATDP1SLC6A2SLC6A3KDM4E
Benzyl Benzoate SCHEMBL29144647 0.85 KMT2A (0.96) KMT2ATDP1SLC6A2SLC6A3KDM4E
Benzyl Benzoate SCHEMBL29007153 0.85 KMT2A (0.96) KMT2ATDP1SLC6A2SLC6A3KDM4E
Benzyl Benzoate SCHEMBL28370886 0.85 KMT2A (0.96) KMT2ATDP1SLC6A2SLC6A3KDM4E
Benzyl Benzoate SCHEMBL27679311 0.85 KMT2A (0.96) KMT2ATDP1SLC6A2SLC6A3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2001019185-A2 METHODS FOR CONTROLLING A PEST POPULATION SUMMUS GROUP, LTD. (US) 2001-03-22 WO claimed
US-5939568-A Accelerated catalysis of olefinic epoxidations THE SCRIPPS RESEARCH INSTITUTE (US) 1999-08-17 US claimed
WO-1998033786-A9 ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS 1998-12-30 WO claimed
WO-1998033786-A1 ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS THE SCRIPPS RESEARCH INSTITUTE (US) 1998-08-06 WO claimed
US-20230405140-A1 ANTI-CD56 ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THERAPY McSAF Inside Oncology (FR) 2023-12-21 US disclosed
US-20230277678-A1 COMPOUNDS CAPABLE OF BINDING TO PROTEINS AND CONJUGATES OBTAINED FROM THESE COMPOUNDS MC SAF (FR) 2023-09-07 US disclosed
US-20230277678-A1 COMPOUNDS CAPABLE OF BINDING TO PROTEINS AND CONJUGATES OBTAINED FROM THESE COMPOUNDS MC SAF (FR) 2023-09-07 US disclosed
US-20230277678-A1 COMPOUNDS CAPABLE OF BINDING TO PROTEINS AND CONJUGATES OBTAINED FROM THESE COMPOUNDS MC SAF (FR) 2023-09-07 US disclosed
CN-116472268-A Compounds capable of binding to proteins and conjugates obtained from these compounds MC SAF公司 2023-07-21 CN disclosed
US-20230203695-A1 Alkaline Composition For Copper Electroplating Comprising A Defect Reduction Agent BASF SE (DE) 2023-06-29 US disclosed
US-20230203694-A1 ALKALINE COMPOSITION FOR COPPER ELECTROPLATING COMPRISING A GRAIN REFINER BASF SE (DE) 2023-06-29 US disclosed
EP-4181964-A1 COMPOUNDS CAPABLE OF BINDING TO PROTEINS AND CONJUGATES OBTAINED FROM THESE COMPOUNDS Mc SAF (FR) 2023-05-24 EP disclosed
CN-104136434-B FGF receptor (FGFR) agonist dimeric compounds thing, its preparation method and its therapeutic use 赛诺菲 2016-07-06 CN disclosed
CN-105085525-A Isoquinoline sulfonyl derivatives as RHO kinases inhibitor NANJING MINGDE NEW DRUG RES AND DEV CO LTD 2015-11-25 CN disclosed
CN-104136434-A FGF RECEPTOR (FGFR) AGONIST DIMERIC COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA 2014-11-05 CN disclosed
US-5939568-A Accelerated catalysis of olefinic epoxidations THE SCRIPPS RESEARCH INSTITUTE (US) 1999-08-17 US disclosed
WO-1998033786-A9 ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS 1998-12-30 WO disclosed
WO-1998033786-A1 ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS THE SCRIPPS RESEARCH INSTITUTE (US) 1998-08-06 WO disclosed
EP-0060144-A2 Cephalosporin antibiotics ELI LILLY AND COMPANY (US) 1982-09-15 EP disclosed
US-4336253-A Cephalosporin antibiotics ELI LILLY AND COMPANY (US) 1982-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230277678-A1 COMPOUNDS CAPABLE OF BINDING TO PROTEINS AND CONJUGATES OBTAINED FROM THESE COMPOUNDS SHBG, SERPINA6, F13B KMT2A 4179/4885TDP1 2580/4885SLC6A2 3209/4885
US-20230405140-A1 ANTI-CD56 ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THERAPY CD47, NCL, EPCAM KMT2A 1437/4885TDP1 1732/4885SLC6A2 587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.